BLLN · BillionToOne, Inc.
$99.16
+0.66% last session
End-of-day data · close of 2026-09-11
Market cap
$5B
Enterprise value
$4B
Trailing P/E
138.8
Forward P/E
66.3
Dividend yield
—
Beta
—
Avg volume
1M
Employees
1K
Daily Change %
0.66%
5 Days Change
-0.23%
10 Days Change
9.36%
30 Days Change
1.25%
60 Days Change
-21.78%
Month to Day Change
7.41%
Year to Day Change
21.16%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BLLN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-02
Latest call per bank · past 12 months
JP Morgan
Overweight$130
+32.0% vs priceWells Fargo
Equal-Weight$90.00
-8.6% vs priceJefferies
Hold$117
+18.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-02 | Canaccord Genuity | Initiates | Buy | $0.00 → $120 |
| 2026-08-06 | JP Morgan | Maintains | Overweight | $145 → $130 |
| 2026-08-06 | BTIG | Maintains | Buy | $142 → $130 |
| 2026-06-29 | Guggenheim | Initiates | Buy | $120 → $125 |
| 2026-05-13 | Guggenheim | Maintains | Buy | $100 → $120 |
| 2026-05-07 | JP Morgan | Maintains | Overweight | $120 → $125 |
| 2026-05-07 | BTIG | Maintains | Buy | $140 → $130 |
| 2026-03-30 | Guggenheim | Maintains | Buy | $120 → $100 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 47 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.5% below the 50-day MA ($112.06).
- Price vs 200-day MA: Trading 4.2% above the 200-day MA ($95.21).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+1.50) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($64.03) and high ($149.97).
BLLN Price Chart
Loading chart for BLLN…
Fundamentals
About BillionToOne, Inc.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
More in Diagnostics & Research
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.